Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ECYT > SEC Filings for ECYT > Form 8-K on 26-Sep-2013All Recent SEC Filings

Show all filings for ENDOCYTE INC

Form 8-K for ENDOCYTE INC


26-Sep-2013

Regulation FD Disclosure


Item 7.01 Regulation FD Disclosure.

Janssen Products, LP informed healthcare providers on September 25, 2013 of an anticipated interruption of supply of DOXILŽ (doxorubicin HCI liposome injection). Endocyte's Phase 3 PROCEED trial evaluating vintafolide and etarfolatide in women with platinum resistant ovarian cancer includes DOXILŽ as the control drug. As previously disclosed, Endocyte has purchased a substantial supply of DOXILŽ to support the PROCEED trial. This supply is expected to be sufficient to support patients currently on trial and new enrollment for the next 9-12 months, which would be beyond the interim analysis of the trial. Enrollment in the trial will continue uninterrupted in the meantime.

Endocyte will continue to collaborate with Janssen to ensure ongoing supply of DOXILŽ in order to complete the PROCEED trial.

  Add ECYT to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ECYT - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.